News articles about Kalvista Pharmaceuticals (NASDAQ:KALV) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kalvista Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 46.3965783759766 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. TheStreet lowered shares of Kalvista Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Wednesday, May 2nd. BTIG Research reaffirmed a “buy” rating on shares of Kalvista Pharmaceuticals in a report on Sunday, April 29th. Finally, Roth Capital assumed coverage on shares of Kalvista Pharmaceuticals in a report on Tuesday, July 10th. They set a “buy” rating and a $20.00 target price for the company.
Shares of KALV stock traded up $0.03 during midday trading on Friday, hitting $12.44. 15,011 shares of the company were exchanged, compared to its average volume of 28,089. The company has a market capitalization of $134.04 million, a price-to-earnings ratio of -8.13 and a beta of 2.53. Kalvista Pharmaceuticals has a 52 week low of $5.48 and a 52 week high of $15.80.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.